A population- and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease

Authors

  • Dr. Mark S. Silverberg,

    Corresponding author
    1. Departments of Medicine, Surgery, Public Health Sciences, Immunology, and Molecular and Medical Genetics, University of Toronto, Samuel Lunenfeld Research Institute and Mount Sinai Hospital, Toronto, Canada
    2. The Toronto General Hospital Research Institute, Toronto, Ontario, Canada
    • Mount Sinai Hospital, 600 University Avenue, Room 441, Toronto, Ontario M5G 1X5, Canada.
    Search for more papers by this author
  • Lucia Mirea,

    1. Departments of Medicine, Surgery, Public Health Sciences, Immunology, and Molecular and Medical Genetics, University of Toronto, Samuel Lunenfeld Research Institute and Mount Sinai Hospital, Toronto, Canada
    2. The Toronto General Hospital Research Institute, Toronto, Ontario, Canada
    Search for more papers by this author
  • Shelley B. Bull,

    1. Departments of Medicine, Surgery, Public Health Sciences, Immunology, and Molecular and Medical Genetics, University of Toronto, Samuel Lunenfeld Research Institute and Mount Sinai Hospital, Toronto, Canada
    2. The Toronto General Hospital Research Institute, Toronto, Ontario, Canada
    Search for more papers by this author
  • Janet E. Murphy,

    1. Departments of Medicine, Surgery, Public Health Sciences, Immunology, and Molecular and Medical Genetics, University of Toronto, Samuel Lunenfeld Research Institute and Mount Sinai Hospital, Toronto, Canada
    2. The Toronto General Hospital Research Institute, Toronto, Ontario, Canada
    Search for more papers by this author
  • A. Hillary Steinhart,

    1. Departments of Medicine, Surgery, Public Health Sciences, Immunology, and Molecular and Medical Genetics, University of Toronto, Samuel Lunenfeld Research Institute and Mount Sinai Hospital, Toronto, Canada
    2. The Toronto General Hospital Research Institute, Toronto, Ontario, Canada
    Search for more papers by this author
  • Gordon R. Greenberg,

    1. Departments of Medicine, Surgery, Public Health Sciences, Immunology, and Molecular and Medical Genetics, University of Toronto, Samuel Lunenfeld Research Institute and Mount Sinai Hospital, Toronto, Canada
    2. The Toronto General Hospital Research Institute, Toronto, Ontario, Canada
    Search for more papers by this author
  • Robin S. McLeod,

    1. Departments of Medicine, Surgery, Public Health Sciences, Immunology, and Molecular and Medical Genetics, University of Toronto, Samuel Lunenfeld Research Institute and Mount Sinai Hospital, Toronto, Canada
    2. The Toronto General Hospital Research Institute, Toronto, Ontario, Canada
    Search for more papers by this author
  • Zane Cohen,

    1. Departments of Medicine, Surgery, Public Health Sciences, Immunology, and Molecular and Medical Genetics, University of Toronto, Samuel Lunenfeld Research Institute and Mount Sinai Hospital, Toronto, Canada
    2. The Toronto General Hospital Research Institute, Toronto, Ontario, Canada
    Search for more papers by this author
  • Judith A. Wade,

    1. Departments of Medicine, Surgery, Public Health Sciences, Immunology, and Molecular and Medical Genetics, University of Toronto, Samuel Lunenfeld Research Institute and Mount Sinai Hospital, Toronto, Canada
    2. The Toronto General Hospital Research Institute, Toronto, Ontario, Canada
    Search for more papers by this author
  • Katherine A. Siminovitch

    1. Departments of Medicine, Surgery, Public Health Sciences, Immunology, and Molecular and Medical Genetics, University of Toronto, Samuel Lunenfeld Research Institute and Mount Sinai Hospital, Toronto, Canada
    2. The Toronto General Hospital Research Institute, Toronto, Ontario, Canada
    Search for more papers by this author

Abstract

The aim of this study was to identify major histocompatibility complex alleles associated with the development and clinical features of inflammatory bowel disease (IBD). Genotyping at the human leukocyte antigen (HLA) DRB1 and DQB1 loci was performed on individuals from 118 Caucasian IBD sibling pair families and on 216 healthy controls. Both population- and family-based association tests were used to analyze data obtained on the entire study population and on clinical subgroups stratified by diagnosis, ethnicity, and disease distribution. HLA DRB1*0103 was significantly associated with IBD (OR = 6.0, p = 0.0001) in a case–control analysis of non-Jewish IBD-affected individuals. This association was apparent among both Crohn's disease (OR = 5.23, p = 0.0007) and ulcerative colitis (OR = 7.9, p = 0.0001) patients and was confirmed in the non-Jewish IBD population by results of family-based association analysis using the transmission disequilibrium test. HLA DQB1*0501 was also associated with IBD (OR = 1.64, p = 0.02) in the non-Jewish population, but statistically significant association of this allele with disease was not detected for Crohn's disease and ulcerative colitis separately. No significant associations were identified among the Jewish patients. In the non-Jewish IBD families, IBD was as strongly associated with the DRB1*0103 DQB1*0501 haplotype as with the DRB1*0103 allele alone. The carrier frequency of the DRB1*0103 allele was found to be 10-fold higher in Crohn's disease patients with pure colonic involvement than in healthy controls (38.5% vs. 3.2%; p = 0.0002). These data demonstrate the association of the HLA DRB1*0103 allele with both Crohn's disease and ulcerative colitis and with large intestine–restricted disease in non-Jewish IBD patients and therefore identify HLA DRB1*0103 as a potentially important contributor to disease susceptibility and to expression of colonic involvement in IBD.

Ancillary